AI
VERV

Alphabet Inc’s Verve Therapeutics VERV Stock Holding History

Alphabet Inc’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12,168,489
Closed -$137M – 38
2025
Q2 		$137M Sell
12,168,489
-180,597
-1% -$1.03M 6.4% 7
2025
Q1 		$56.4M Hold
12,349,086
– – 3.58% 11
2024
Q4 		$69.6M Hold
12,349,086
– – 4.06% 9
2024
Q3 		$59.8M Hold
12,349,086
– – 3.24% 10
2024
Q2 		$60.3M Hold
12,349,086
– – 3.05% 10
2024
Q1 		$164M Hold
12,349,086
– – 6.52% 7
2023
Q4 		$172M Buy
12,349,086
+1,800,000
+17% +$22.3M 7.98% 4
2023
Q3 		$140M Hold
10,549,086
– – 8.98% 3
2023
Q2 		$198M Hold
10,549,086
– – 10.63% 2
2023
Q1 		$152M Hold
10,549,086
– – 8.43% 5
2022
Q4 		$204M Sell
10,549,086
-424,925
-4% -$11.3M 11.86% 2
2022
Q3 		$377M Hold
10,974,011
– – 19.25% 1
2022
Q2 		$168M Hold
10,974,011
– – 9.1% 4
2022
Q1 		$250M Hold
10,974,011
– – 8.13% 4
2021
Q4 		$405M Hold
10,974,011
– – 9.77% 2
2021
Q3 		$516M Hold
10,974,011
– – 12.24% 2
2021
Q2 		$661M Buy
+10,974,011
New +$456M 13.47% 2

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Alphabet Inc's VERV Position: Q3 2025 in Review

Alphabet Inc sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 12,168,489 shares — an estimated $137M sold.

Alphabet Inc first reported a position in VERV in Q2 2021 and held it in 17 quarters. The position peaked at $661M in Q2 2021. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Alphabet Inc reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Alphabet Inc sold 12,168,489 Verve Therapeutics shares in Q3 2025, an estimated $137M.
  • Alphabet Inc first reported a position in Verve Therapeutics in Q2 2021 and held it in 17 quarters.
  • Alphabet Inc's Verve Therapeutics position peaked at $661M in Q2 2021.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Alphabet Inc's 13F filing for Q3 2025, filed 7 Nov 2025.